Furthermore, miR221/222 are reported to reduce p57Kip2 and p27Kip1 expression in hepatocarcinoma [164], in glioblastoma [165], in oral cancer [166], in colorectal cancer [167] and B-cell malignancies EBV-associated [168] Experimental data confirmed, at least in ovarian cancers, the specific action of miR-221/222 on CDKN1C [169]. Here, CDKN1C is linked to lip and oral cavity carcinoma.